Malignant hyperthermia (MH) is a rare but potentially life-threatening disorder encountered during general anesthesia. The use of cardiopulmonary bypass during cardiac surgery can obscure many of the cardinal signs and symptoms of MH. The development of postoperative MH following cardiac surgery is rare, but anesthesiologists and intensivists must maintain a high index of suspicion in order to make a prompt diagnosis. Initiation and tailored maintenance of MH therapy must also consider the complex physiologic changes of patients in the immediate post-cardiac surgery period. In this article, we present a case of the development of postoperative MH in the cardiac intensive care unit after elective open heart surgery with cardiopulmonary bypass.
Introduction
Malignant hyperthermia (MH) is a rare hypermetabolic skeletal muscle disorder that can be triggered by multiple agents during general anesthesia. Typical inciting substances include inhaled volatile anesthetics and the depolarizing neuromuscular blocker succinylcholine. Susceptibility to MH is inherited genetically in an autosomal dominant pattern with a prevalence as high as 1 in 3000 in the general population 1 and an overall incidence between 0.5 to 2 in 100 000 general anesthetics. [2] [3] [4] [5] Genetic MH susceptibility is due to variations in specific genes that are involved in skeletal muscle calcium regulation and contraction. The 2 main identified gene mutations are variations of the RYR1 and CACNA1S genes, which account for MH susceptibility type 1 and type 5, respectively. The RYR1 gene encodes the type 1 ryanodine receptor of skeletal muscle. Mutations in the RYR1 gene account for approximately 70% to 80% of the individuals with confirmed genetic MH susceptibility. 6 The CACNA1S gene encodes the alpha-1 subunit of the skeletal muscle dihydropyridine receptor L-type calcium channel. CACNA1S gene mutations are less common and only account for approximately 1% of all genetic MH susceptibilities. 6 The incidence varies by population with an estimated prevalence between 1 in 2000 and 1 in 3000 for 1 of these 2 causative gene variants. 6 When it occurs, MH leads to uncontrolled calcium release in skeletal muscle leading to sustained contraction, muscle rigidity, metabolic acidosis, hyperthermia, and rhabdomyolysis. Without rapid recognition and treatment with dantrolene to block the release of intracellular calcium, multi-organ failure and death can rapidly ensue. 7, 8 The signs and symptoms of MH usually present immediately after the administration of a triggering agent during the general anesthetic and operation; however, there are reported cases in which the onset of MH began after surgery in the postoperative period. 9 Postoperative MH is rare, occurring in only 1.9% of suspected MH cases reported to the North American Malignant Hyperthermia Registry (NAMHR). The recognition of MH can be made even more difficult during cardiac surgery because the use of cardiopulmonary bypass (CPB) and associated hypothermia can obscure the more traditional signs and symptoms of MH, potentially leading to a delayed diagnosis. Our case provides a unique example of the delayed initial 1 The Ohio State University Wexner Medical Center, Columbus, OH, USA presentation of MH, and the specific MH treatment considerations in the cardiac patient.
Case Report
A 53-year-old man underwent elective 2-vessel coronary artery bypass grafting (CABG) with hypothermic CPB, after presenting with new chest pain and a remote history of percutaneous coronary intervention to the right coronary artery and left anterior descending artery. Diagnostic workup revealed significant coronary artery disease, and he was referred for CABG. His preoperative anesthetic evaluation was not significant for any anesthetic problems in the past or that ran in family, and there was no personal or family history of MH. He had one prior uneventful general anesthetic for a herniorrhaphy.
The anesthetic induction consisted of midazolam (8 mg), etomidate (20 mg), fentanyl (250 g), and rocuronium (100 mg). The patient was maintained on isoflurane vapor with fentanyl and vecuronium infusions. Arterial blood gas analyses were performed during the case and his core temperature was monitored continuously. He received heparin and protamine before and after CPB. The patient was rewarmed and separated from CPB without requiring calcium or epinephrine for inotropic support. Of note, intraoperatively there was no evidence of metabolic acidosis (nadir pH on patient's arterial blood gas measurements was 7.35) or hyperthermia based on the patient's arterial blood gases and core temperature measurements. At the end of the case, the patient was taken fully ventilated with complete neuromuscular blockade to the cardiac intensive care unit. The final core temperature as the patient left the operating room was 35.7°C.
On arrival to the cardiac intensive care unit (ICU), the patient's neuromuscular blockade was antagonized with neostigmine and glycopyrrolate. Shortly thereafter the patient was noted to be biting down on his endotracheal tube. The arterial blood gas collected at this time demonstrated a pH of 7.36 with a PCO 2 of 46 mm Hg, base excess of 3.0 mmol/L, bicarbonate of 24.3 mmol/L, and a lactate of 3.28 mmol/L. Physical exam revealed a core temperature of 37.5°C with extreme muscle rigidity in both flexor and extensor muscles in both upper and lower extremities. Over the next hour the patient's temperature rose from 37.5°C to 39.8°C and his next arterial blood gas demonstrated a pH of 7.28 with a PCO 2 of 52 mm Hg, base excess of 4.2 mmol/L, bicarbonate of 23.5 mmol/L, and a lactate of 4.29 mmol/L, despite mechanical ventilation with assist control ventilation with a minute ventilation of 15 to 17 L/ min. The muscle rigidity was present even with a continuous propofol infusion for sedation. Given the persistent muscle rigidity, worsening metabolic acidosis, and hyperthermia, the diagnosis of MH was suspected. Alternative diagnoses at the time included sepsis and neuroleptic malignant syndrome; the patient had received one dose of intravenous (IV) haloperidol 5 mg for possible emergence delirium. Both were felt to be less likely than MH. The Malignant Hyperthermia Association of the United States (MHAUS) was contacted and dantrolene was ordered. The patient was actively cooled while awaiting dantrolene and weaned from sedation. He was following commands briskly and was moving all extremities. A creatinine kinase (CK) level peaked at 3400, and urine myoglobin testing was negative. Of note, there were no gross urine color changes in the operating room or in the ICU. Active cooling was performed with a cooling blanket, ice packs, and finally a femoral cooling catheter was required. The patient received fluid loading for resuscitation, furosemide (3 doses of 20 mg, 20mg, and 10 mg, respectively), and sodium bicarbonate (2 doses of 50 mEq each). Dantrolene, in the form of Dantrium (dantrolene sodium), was given with an initial dose of 2.5 mg/kg IV (225mg in 675 mL of sterile water) and was repeated every 15 minutes for 4 total doses. The patient then received doses of 1 mg/kg (100 mg in 300 mL of sterile water) every 6 hours for 4 doses. The time interval from arrival to ICU to when dantrolene was administered was approximately 1 hour, whereas the time interval from suspicion of MH to dantrolene administration was approximately 20 minutes. The patient did have an acute rise in his serum potassium, which resulted in a nephrology consultation for possible continuous renal replacement therapy. Prior to consultation the patient was treated with standard medical therapy for hyperkalemia including insulin (10 units of regular IV) and dextrose (50 g), furosemide (50 mg total over 3 doses of 20 mg, 20 mg, and 10 mg, respectively), and 2 doses of sodium bicarbonate (50 mEq each). The patient was not given calcium as part of the hyperkalemia treatment at this time from recommendation of the MHAUS consultant given there were no cardiac disturbances on EKG consistent with hyperkalemia. The patient responded to dantrolene therapy and body temperature decreased to below 36.6°C within 3 hours. Over the course of the night, the patient remained endotracheally intubated and sedated with stable hemodynamics. During his dantrolene therapy, his hyperpyrexia, metabolic acidosis, and CK levels improved. The patient's hourly urine output during the MH crisis was 1.0 L/hour for the first 3 hours and then consistently remained above 2 mL/kg/h through the next 24 hours. The patient was successfully extubated the following evening on postoperative day one after maintaining normothermia for 24 hours. The subsequent postoperative course was unremarkable and the patient was discharged home on postoperative day 7. The patient was given proper MH counseling (including the need for a medical alert wristband, MH being added to his medical record, and listing allergies to isoflurane, sevoflurane, desflurane, and succinylcholine). Familial counseling was given and recommended in addition to the potential for future muscle biopsy for diagnosis confirmation. Since discharge, we have reached out directly to the patient to see if any additional genetic or biopsy testing was completed; however, the MHAUS team felt the diagnosis was likely, and so they did not urge further testing at the time of the index incident.
Discussion
We report a case of a patient who developed MH in the postoperative period following cardiac surgery. This case highlights the diagnostic and treatment challenges of MH in the post-cardiac surgery patient.
Postoperative MH is extremely rare, with the majority of reported cases of MH occurring during the administration of triggering agents. 10 A large review of MH cases reported to the NAMHR found that only 10 of the 528 cases reported to NAMHR (1.9%) represented postoperative MH with initial presentation occurring after the conclusion of the general anesthetic. 9 The nature of cardiac surgery and specifically CPB can make a preliminary diagnosis of MH challenging. Furthermore, the development of MH during or after cardiac surgery with CPB is extremely rare. A 2011 systematic review of published cases found only 24 case reports and case series that involving suspected MH during or after cardiac surgery with CPB. Of these case reports only 11 cases were identified that were consistent with the diagnosis of MH after but not during CPB. 10 The detection of MH in the postoperative period after cardiac surgery using CPB can be difficult because the classic symptoms can be misinterpreted or obscured (Table 1) . Many of the typical symptoms of MH can be attributed to other factors involved in cardiac surgery with CPB. One of the earliest symptoms of MH is an increase in arterial PCO 2 secondary to increased cellular metabolism from hypermetabolic rampant muscle contraction. 10 However, during CPB PCO 2 is not continuously measured. This combined with the fact that the sweep gas flow is typically controlled by a perfusionist (not the anesthesiologist) who actively corrects the PCO 2 based on serial arterial blood gas measurements. Hemodynamic instability with arrhythmias can be consistent with early signs of MH, but during CPB hemodynamics are relatively well controlled due to relatively constant and controllable flow rates. It is not uncommon to see large fluctuations in hemodynamic parameters in normal patients separating from CPB, which again can potentially mask the symptoms that might otherwise align with a diagnosis of MH. Patients with MH, because of sustained muscle contraction, can also develop rhabdomyolysis, which can lead to cell lysis and increased release of intracellular potassium stores leading to hyperkalemia. These 2 signs can be challenging to diagnose during CPB because CK levels, indicative of rhabdomyolysis, are not typically drawn during CPB and hyperkalemia can be attributed to administration of cardioplegia. During CPB sustained muscle relaxation is imperative not only for optimal surgical conditions but also to decrease the total body oxygen consumption and help reduce the risk for myocardial ischemic. CPB may result in hemolysis causing urinary discoloration that may potentially present a confounding sign mimicking myoglobinuria. The use of large dose of nondepolarizing muscular blockers or infusions can often confound identifying muscle rigidity as a symptom of MH during CPB. Finally, CPB is used for controlled hypothermia to decrease total body oxygen consumption. Although hyperpyrexia is traditionally considered a late sign of MH, it is hard to appreciate during CPB as patients are actively cooled. Hyperthermia may therefore only present after the cessation of CPB. Furthermore, there is evidence that rewarming during CPB may trigger MH, even in the absence of any other potential triggering agents. 8 Active cooling during CPB may mask the development of MH. Therefore, any patient at risk for MH may be rewarmed carefully during CPB and that aggressive rewarming is effectively contraindicated. MH can result in significant multi-organ failure, morbidity, and death if not rapidly recognized and treated appropriately. Treatment of MH in cardiac surgery patients must both be aggressive and tailored to their specific physiology, which can be clinically challenging (Table 2) . Additional concern is warranted for postoperative cardiac patients because they are at a higher risk for myocardial ischemia compared to non-cardiac surgery patients. 12 These patients are less likely to tolerate the augmented cardiac output demanded by the increased oxygen consumption and hypermetabolic state encountered during an acute MH crisis. The mainstay of MH therapy is prompt treatment with dantrolene to decease the hypermetabolic state. Dantrolene's mechanism of action is to depress skeletal muscle contraction by binding to the ryanodine receptor and thereby decreasing the intracellular calcium concentration. Common side effects of treatment can include, but are not limited to, pulmonary edema, urticaria, erythema, thrombophlebitis, tissue necrosis, decreased strength, weakness, vision changes, and dizziness. Treatment of these patients with dantrolene can be complicated by the volume required to reconstitute dantrolene. Specifically, large volumes of fluid may not be well tolerated by patients with cardiac dysfunction. In our patient's case, he required approximately 3.9 L (4 doses of 675 mL of sterile water each for his initial 2.5 mg/kg loading doses and then 4 doses of 300 mL of sterile water each for his subsequent 1 mg/kg maintenance doses) of fluid just to reconstitute the appropriate amount of dantrolene for his initially treatment. Many patients can be exquisitely sensitive to large volumes of fluid administration, which can worsen or precipitate heart failure. Of note, Ryanodex ® , the newer form of dantrolene sodium, allows for faster reconstitution and administration, with just one vial providing a loading dose (2.5 mg/kg) of dantrolene sodium for most patients, and only requires reconstitution with 5 mL of sterile water for injection. MH patients can also potentially develop rhabdomyolysis for which euvolemic polyuria is the indicated treatment. Assessments of volume status during these resuscitative maneuvers are also complicated by the changing systemic vascular resistance and venous compliance of the postoperative cardiac surgery patient. Rhabdomyolysis, diuretic, and rapid fluid administration also increase the risk of acute kidney injury, which occurs in up to 30% of cardiac surgery patients. 13 Kidney injury severe enough to require renal replacement therapy may further increase mortality up to 8-fold in this population. 14 The risk of acute kidney injury may be mitigated by use of invasive monitoring and critical care. For these patients early institution of renal replacement therapy may be indicated not only for volume management but also for potential electrolyte derangements including hyperkalemia. Data would suggest at least a third of postcardiac surgery patients require a blood transfusion post CABG. 15 Citrated blood products may lead to transient hypocalcemia, which may prompt calcium administration. Careful thought must be given with regard to calcium administration during an MH crisis as there is some equivocal evidence that calcium might theoretically exacerbate MH. However, MHAUS specifically recommends the administration of calcium if hyperkalemia is present and therefore should be given in this circumstance as the benefits likely outweigh the risks.
Conclusion
We present a case of MH developing postoperatively in the cardiovascular intensive care unit after an elective 2-vessel coronary artery bypass grafting with CPB. MH is a rare genetic inherited disorder of sustained skeletal muscle contraction in which the classic signs can be difficult to appreciate in the setting of CPB. Treatment of MH must be aggressive and swift with dantrolene but also specifically tailored to each patient to account for their underlying physiology and potential side effects of treatment. Anesthesiologists and intensivists must be vigilant in order to make a rapid diagnosis and quickly institute potentially lifesaving treatment. 
